Back to Search
Start Over
The Efficacy of Rituximab in High-risk Renal Transplant Recipients
- Source :
- Scopus-Elsevier, ResearcherID
- Publication Year :
- 2016
-
Abstract
- Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients.
Details
- ISSN :
- 0386300X
- Volume :
- 70
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Acta medica Okayama
- Accession number :
- edsair.pmid.dedup....f1c0138363d29887e1a56ddd1322c294